FDA Setback and Stock Impact
Corcept Therapeutics (NASDAQ: CORT) suffered a dramatic 50% stock plunge on December 31, 2025, after the FDA refused to approve its lead pipeline drug relacorilant ([1]). The company announced it had received a Complete Response Letter (CRL) for relacorilant – intended to treat hypertension in Cushing’s syndrome (hypercortisolism) – meaning the FDA concluded it could not grant approval without additional evidence of the drug’s effectiveness ([2]). This surprise rejection sparked a violent repricing of Corcept’s shares, which opened near $70 but collapsed to an intraday low around $33.80 that day (versus a prior $70.19 close) ([1]). Over $3.6 billion in market value was erased, reflecting investors’ concern that a key growth driver had been derailed ([3]). Relacorilant was widely expected to become Corcept’s next cornerstone therapy and reduce its heavy reliance on the company’s sole marketed product, Korlym. The FDA’s demand for more efficacy data immediately cast doubt on Corcept’s growth narrative, which had hinged on relacorilant’s successful launch ([4]) ([4]).
Dividend Policy and Shareholder Returns
Corcept does not pay any dividend and has never declared cash dividends on its common stock ([5]) ([5]). Management has instead favored share repurchases as the method of returning capital to shareholders. Notably, in late 2021 Corcept completed a large tender offer, buying back 10 million shares at $20.75 for about $207.5 million ([5]). The Board has also authorized open-market repurchase programs at various times – for example, a $200 million stock buyback authorization was approved in January 2024 ([5]). These buybacks have significantly reduced the company’s outstanding share count (from ~126 million diluted shares in 2021 to ~112 million in 2023 ([5])), which boosted Corcept’s EPS growth. With no dividend yield (0%), any shareholder returns have come via stock price appreciation and these repurchase programs. The aggressive buybacks reflect confidence in the company’s prospects, though investors now question whether that capital could have been better allocated given recent setbacks.
Balance Sheet, Leverage and Debt Maturities
Corcept enters this period of uncertainty in a strong financial position with virtually no debt. The company carries no outstanding long-term loans or bonds – total liabilities were $114.8 million as of year-end 2023, consisting mainly of accounts payable, accrued expenses, and tax liabilities ([5]). This gave Corcept a negligible debt-to-equity ratio (~0.01) ([6]). In fact, the company’s current assets (cash, investments, receivables) of $458.6 million far outweigh its total liabilities ([5]) ([5]). Liquidity is strong with a current ratio above 3× ([6]), and the firm has built a large cash and securities reserve (over $350 million in cash and short-term investments at 2023 year-end) to fund R&D and operations. With effectively zero net debt, traditional leverage and interest coverage metrics are a non-issue – Corcept’s operating cash flows have been funding its growth initiatives without requiring external borrowing. The lack of debt maturities or interest obligations provides management with flexibility as they navigate the FDA setback. However, investors should monitor if the company’s cash burn increases (for potential new trials or litigation) which could eventually pressure Corcept to tap its cash pile or seek financing. For now, the balance sheet strength and lack of leverage serve as a cushion against near-term challenges.
Operating Performance and Valuation
Despite being a biotech, Corcept is unusual in that it has an established revenue base and consistent profitability. The company’s sole product Korlym (mifepristone) – a cortisol-blocking therapy for endogenous Cushing’s syndrome – has been generating steady growth. In 2023, Corcept reported net product revenue of $482.4 million, up 20% from the prior year ([5]), with net income of $106 million ([5]). That momentum continued into 2024–2025: for the first nine months of 2025 Korlym sales reached $559.3 million (a ~13% YoY increase) ([7]). Management had projected full-year 2025 revenue of roughly $800–850 million ([7]) – nearly double the company’s 2021 sales – reflecting deeper market penetration and price increases for Korlym. However, Korlym is still the sole contributor to Corcept’s top line ([7]), so overall growth has been capped by the size of the Cushing’s syndrome patient population and any bottlenecks in distribution. (Indeed, earlier in 2025 Korlym sales were temporarily constrained by capacity issues at Corcept’s specialty pharmacy provider, though the company added new distributors to resolve the problem ([7]).)
In terms of valuation, Corcept’s stock had run up significantly in anticipation of relacorilant’s approval, leaving its trading multiples elevated. Even after the recent plunge to the mid-$30s per share, CORT trades around 38× trailing earnings, which is higher than the ~33× average for small-cap biotech peers and well above the broader U.S. pharma industry’s ~20× P/E ([8]). On an absolute basis, the stock’s P/E in early 2026 is about 38–43 (depending on exact earnings used) ([6]) ([8]) – suggesting that the market was pricing in substantial future growth from the pipeline. Traditional REIT metrics like FFO/AFFO are not applicable here; investors focus instead on Corcept’s PE ratio and growth outlook. By comparison, prior to the FDA news CORT was trading north of 70× earnings, reflecting high expectations for relacorilant’s commercial potential. The stock’s compression in valuation multiples (to ~38×) indicates some risk premium has been priced in, but Corcept still isn’t “cheap” relative to current earnings. Bulls argue that earnings will grow rapidly if the pipeline succeeds, while bears note that at ~38× earnings the stock leaves little margin for error if growth falters ([8]). Wall Street analysts likewise remain divided. After the CRL, several analysts slashed their price targets – for example, Canaccord cut its target from $140 to $99, and H.C. Wainwright reduced its target from $145 to $90 ([6]). One firm (Wolfe Research) went as far as downgrading CORT to Underperform with a $30 target amid the uncertainty ([6]). Even so, the consensus target price still sits around $80 per share ([6]), implying that many analysts see significant upside if Corcept can get back on track. This wide range of valuations underscores the binary nature of Corcept’s story at this juncture – the stock’s fair value will swing dramatically based on the outcome of its drug development and competitive dynamics in the coming years.
Key Risks and Red Flags
Several risk factors and red flags have become apparent in Corcept’s investment case, especially following the recent developments:
– Reliance on a Single Product: Corcept’s revenue is entirely dependent on Korlym, which treats a rare condition and faces natural market limitations ([7]). This concentration makes the company vulnerable – any downturn in Korlym sales would directly and significantly impact earnings ([5]) ([4]). Management has openly acknowledged that failure to sustain Korlym’s revenue growth would harm financial results and likely hurt the stock price ([5]) ([5]). Until relacorilant or other candidates are approved, Corcept lacks alternative revenue streams to diversify risk.
– Generic Competition and Patent Challenges: The patent exclusivity on Korlym is under threat. Korlym’s orphan drug exclusivity expired in 2019, and multiple generic drug makers have sought FDA approval to launch generic mifepristone for Cushing’s syndrome ([5]). Corcept has been embroiled in patent litigation to block these generics. In late 2023, a U.S. district court ruled that Teva’s proposed generic Korlym does not infringe Corcept’s patents, clearing a path for Teva to enter the market ([5]) ([5]). Corcept is appealing the decision, but notably Teva has already announced the launch of its generic Korlym ([5]). If Teva’s generic gains traction, Corcept’s Korlym sales and pricing could decline rapidly, materially eroding revenue and profits ([5]) ([5]). Corcept has also settled patent lawsuits with Sun Pharma and Hikma, allowing those companies to release generics in the future after Teva’s entry ([5]). This means more than one generic could be on the market in coming years. The prospect of low-cost generics presents a serious risk to Corcept’s core business, and the timing/impact of generic competition remains a key uncertainty. Thus far, Korlym sales have continued to grow, but investors fear an inflection point if payers and patients begin switching to generic mifepristone in significant numbers.
– New Competition in Cushing’s Syndrome: Aside from generics, novel therapies for Cushing’s syndrome have recently emerged. Recordati’s Isturisa (osilodrostat) and Xeris’ Recorlev (levoketoconazole) were approved in 2020–2021 and also target endogenous Cushing’s ([5]). These drugs use different mechanisms (adrenal steroid synthesis inhibition) and could appeal to physicians or patients who want alternatives to Korlym. Corcept itself warns that the availability of competing treatments – including off-label older drugs like ketoconazole, and new branded options – could limit Korlym’s revenue and market share ([5]). If physicians prefer these newer treatments (which don’t carry Korlym’s side-effect of pregnancy termination risk, for example), Korlym’s growth could stall. Increased competition may also pressure Corcept to moderate Korlym’s price increases or invest more in marketing to defend its share.
– Regulatory Setback for Relacorilant: The FDA’s rejection of relacorilant is a major blow to Corcept’s pipeline. Relacorilant was central to the bull thesis, positioned as the next-generation cortisol modulator to eventually replace Korlym and drive new growth ([4]). The CRL raises questions about the drug’s approvability – notably, FDA requested additional efficacy evidence despite positive Phase 3 trial results ([2]). This could mean Corcept must conduct another clinical trial or significant data analysis, likely delaying approval by years. In the meantime, Corcept remains wholly reliant on Korlym (just as generic competition is ramping up). The FDA’s stance also casts doubt on Corcept’s broader pipeline of cortisol modulators, since relacorilant uses a similar mechanism as other earlier-stage candidates ([4]). Investors are concerned that if relacorilant’s data were not deemed sufficient, other pipeline programs might face high regulatory hurdles as well. The situation leaves Corcept’s path to near-term revenue diversification unclear, with no other late-stage products ready for market ([4]).
– Management Credibility and Legal Exposure: Prior to the CRL, Corcept’s management had been extremely bullish about relacorilant and the company’s growth prospects. Executives publicly stated that relacorilant’s strong efficacy would make it the “new standard of care” in hypercortisolism and spoke of being “more confident than ever” in achieving $3–5 billion in annual revenue from its hypercortisolism franchise within 3–5 years ([3]). This lofty guidance now appears overly optimistic given the FDA setback. The drastic divergence between management’s assurances and the regulatory outcome has drawn scrutiny. A shareholder rights law firm (Hagens Berman) announced an investigation into whether Corcept misled investors by overstating relacorilant’s efficacy and commercialization timeline ([3]). While no lawsuit has been filed yet, the inquiry highlights a reputational red flag – investors must question the reliability of management’s forecasts. Going forward, Corcept’s communications will be under the microscope, and the company could face class-action litigation if shareholders allege any material misrepresentations around relacorilant.
– Drug Pricing and Policy Overhang: Like other pharmaceutical companies, Corcept is exposed to a changing regulatory environment on drug pricing and reimbursement. U.S. healthcare reforms – such as the Inflation Reduction Act – aim to control medication costs, and future rules could potentially pressure Korlym’s pricing or profitability. However, Korlym’s orphan-drug status and relatively small Medicare usage may shield it from near-term price negotiation mandates ([5]). This risk is more long-term and uncertain, but it adds another layer of caution for investors, especially if Corcept’s drugs were to become more widely used (expanding payer scrutiny).
In sum, Corcept faces a confluence of risks: an impending battle with generics; dependence on a single aging product; a delayed pipeline catalyst; and questions around management’s guidance. These red flags suggest a need for prudent risk management and realistic expectations as the company works to regain momentum.
Outlook and Open Questions
With its stock reeling and relacorilant’s approval delayed, Corcept’s path forward is uncertain. A critical immediate step will be the company’s meeting with the FDA to clarify what “additional evidence of effectiveness” is required for relacorilant ([2]). Open questions include: Will a new clinical trial be needed, and if so, how long might it take? CEO Joseph Belanoff has expressed confidence that they will “find a way to get relacorilant to patients” and intends to work with regulators “as soon as possible” on a path forward ([2]). However, investors have scant visibility on the timeline – a fresh Phase 3 trial could mean a multi-year delay, whereas a smaller study or data analysis might be resolved sooner.
Another pressing question is how Korlym will hold up in the face of generic competition. Now that Teva has launched a generic version of Korlym in the U.S. ([5]), will Corcept’s sales begin to erode in 2026? Thus far, Korlym’s growth has been resilient, but it’s unclear if that can continue once payers start favoring a cheaper generic. The magnitude and pace of Korlym’s revenue decline (if any) will heavily influence Corcept’s financial health and its ability to fund development of new drugs. Management’s 2025 revenue guidance (originally ~$900 million) may need to be revisited if Korlym faces pricing pressure or share loss. Investors will be watching upcoming earnings reports for any signs of generic impact on Korlym prescriptions and margins.
Corcept’s pipeline milestones will also shape its narrative in the coming year. Importantly, relacorilant is still under FDA review in a different indication – as a treatment for platinum-resistant ovarian cancer, with a PDUFA decision date set for July 11, 2026 ([2]). That approval (based on the separate clinical trial in oncology) could provide a boost if successful, opening a new market for relacorilant. However, it targets a narrow patient population and would not immediately replace Korlym’s revenue scale. Will the FDA’s hesitancy on relacorilant’s Cushing’s use carry over to oncology? The company will find out mid-2026. Beyond relacorilant, Corcept has other earlier-stage candidates (e.g. miricorilant for NASH and antipsychotic-induced weight gain) but those are years away from potential approval ([5]) ([5]). Given the long development timelines, another open question is whether Corcept might pursue strategic alternatives – such as partnerships or acquisitions – to bolster its pipeline or monetize its cortisol modulation expertise while it weathers this storm.
In summary, Corcept Therapeutics faces a challenging road ahead. The recent 50% stock drop reflects a sharp reset of expectations, but the company still retains valuable assets: a profitable orphan drug business, deep domain knowledge in cortisol biology, and a debt-free balance sheet. How management navigates the FDA’s requirements and the Korlym generic threat will determine if CORT’s stock can recover. Investors are seeking clearer answers on these open issues in the coming quarters. For now, caution is warranted – Corcept must execute well under heightened scrutiny to regain investor confidence in the wake of its FDA setback. The potential is there, but so are the pitfalls, making CORT a high-risk, high-reward story going forward.
Sources: Corcept 2023 10-K and SEC filings ([5]) ([5]); Company press release and Business Wire (Jan 1, 2026) ([2]) ([2]); Nasdaq/RTTNews market report ([1]) ([1]); Investing.com news ([9]); Zacks Equity Research ([7]) ([7]); Simply Wall St analysis ([8]); Trefis research commentary ([4]); Hagens Berman investor alert ([3]) ([3]); Corcept risk factor disclosures ([5]) ([5]) ([5]) ([5]); MarketBeat/DefenseWorld analyst summary ([6]) ([6]).
Sources
- https://nasdaq.com/articles/corcept-stock-plunges-50-after-fda-rejects-relacorilant-application
- https://biospace.com/press-releases/corcept-receives-complete-response-letter-for-relacorilant-as-a-treatment-for-patients-with-hypercortisolism
- https://prnewswire.com/news-releases/corcept-therapeutics-cort-faces-investor-scrutiny-amid-receipt-of-fda-complete-response-letter-for-relacorilant-shares-tank-50–hagens-berman-302653971.html
- https://trefis.com/articles/586368/corcept-stock-12-fda-rejection-of-relacorilant-reshapes-thesis/2025-12-31
- https://sec.gov/Archives/edgar/data/1088856/000162828024005055/cort-20231231.htm
- https://defenseworld.net/2026/01/03/corcept-therapeutics-nasdaqcort-price-target-cut-to-99-00-by-analysts-at-canaccord-genuity-group.html
- https://nasdaq.com/articles/will-korlym-continue-drive-corcepts-top-line-2026
- https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-reassessing-valuation-after-fda-co
- https://ng.investing.com/news/stock-market-news/corcept-therapeutics-stock-plunges-after-fda-rejects-hypercortisolism-drug-93CH-2270825
For informational purposes only; not investment advice.